PARADOXICAL EFFECT OF ARTIFICIAL TEAR DROP USE ON SIGNS AND SYMPTOMS OF DRY-EYE DISEASE

Parisa Emami-Naeini\textsuperscript{1,2}, MD, MPH, Francisco Amparo\textsuperscript{2}, MD, MSc, Reza Dana\textsuperscript{2}, MD, MPH

\textsuperscript{1} Kresge Eye Institute, Wayne State University, Detroit, MI
\textsuperscript{2} Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA

The authors have no financial disclosure related to this project.
This study was supported in part by grant K24 EY019098 from the National Institutes of Health.
INTRODUCTION

- Dry eye disease (DED) is a common pathology of the ocular surface and tear film.
- An estimated 9 million people are affected by DED in the United States alone.
- DED presents with deficient tear production, unstable tear film (rapid evaporation) or both.
- Pathophysiology is not fully understood. However, tear hyperosmolarity, ocular surface inflammation and corneal epithelial damage are commonly present.
- Symptoms include burning, irritation, foreign body sensation, grittiness, eye fatigue, and redness, among others.
- Persistence of symptoms in combination with fluctuating visual function can significantly diminish patients’ quality of life and social functioning.
- DED patients are more likely to suffer from symptoms of depression and anxiety compared to the normal population.
OBJECTIVES

• Primary:
  • To evaluate the effect of artificial tears on signs and symptoms of DED.

• Secondary:
  • To evaluate the effect of artificial tears in patients with mild/moderate vs. severe DED.
PATIENTS AND METHODS

- Prospective study.
- A total of 30 patients 18 years or older suffering from symptoms of DED and positive corneal fluorescein staining (CFS) were included.
- Subjects were started on carboxymethyl cellulose artificial tear drops three times a day in addition to their current DED treatment regimen (including warm compresses, eyelid scrubs and other artificial tear drops).
- All ocular immunomodulatory medications, including topical corticosteroids and cyclosporine, were stopped two weeks prior to starting the study.
- Patients were followed for 12 weeks with evaluations at baseline and weeks 2, 6 and 12.
- Evaluations included:
  - Symptoms: the Ocular Surface Disease Index (OSDI®) questionnaire
  - Signs: CFS (modified Oxford Grading Scale, score range: 0-5), tear break up time (TBUT) and Schirmer test
- For subgroup analysis, DED severity was categorized into mild/moderate and severe disease according to CFS (19 patients with CFS≤2 [Mild/moderate] and 11 patients with CFS>2 [severe])
MEAN CHANGE IN SIGNS/SYMPTOMS FROM BASELINE

- Mean Change From Baseline
  - CFS
  - TBUT
  - Schirmer
  - OSDI®

* p=0.02
MEAN CHANGE IN CFS FROM BASELINE: MILD/MODERATE VS. SEVERE DED

* p=0.02
MEAN CHANGE IN OSDI© SCORE FROM BASELINE: MILD/MODERATE VS. SEVERE DED

p=0.09
SUMMARY

- CFS improved significantly over the course of treatment (p=0.02).
- After subgroup analysis (mild/moderate vs. severe DED), improvement in CFS maintained statistical significance only in patients with severe DED (p=0.02 in severe vs. p=0.39 in mild/moderate DED).
- OSDI© scores did not change significantly (p=0.1) in DED patients.
- OSDI© scores revealed an increasing trend in patients with severe DED (p=0.09), suggesting exacerbation in patient discomfort.
- There was no significant improvement in Schirmer scores (p=0.91) or TBUT (p=0.2).
CONCLUSION

• Artificial tear drop use significantly improves corneal epitheliopathy (as measured by CFS) in patients with DED, particularly in those with severe disease.

• Interestingly, a modest improvement of staining in severe DED is associated with a “paradoxical” worsening of symptoms, which we speculate could be secondary to corneal nerve regeneration.


Contact info:
Parisa Emami-Naeini (pemamina@med.wayne.edu)
Reza Dana (reza_dana@meei.harvard.edu)